Harvest Portfolios Group Inc. Sells 39,131 Shares of Astrazeneca Plc $AZN

Posted by George Bondi on May 20th, 2026

Harvest Portfolios Group Inc. decreased its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 4.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 754,813 shares of the company’s stock after selling 39,131 shares during the quarter. Astrazeneca comprises 2.3% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 13th largest holding. Harvest Portfolios Group Inc.’s holdings in Astrazeneca were worth $132,470,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC raised its holdings in Astrazeneca by 139.2% during the 4th quarter. Larson Financial Group LLC now owns 2,957 shares of the company’s stock worth $519,000 after buying an additional 1,721 shares during the period. Profund Advisors LLC raised its holdings in Astrazeneca by 9.5% during the 4th quarter. Profund Advisors LLC now owns 54,072 shares of the company’s stock worth $9,490,000 after buying an additional 4,684 shares during the period. ProShare Advisors LLC boosted its position in Astrazeneca by 42.4% during the 4th quarter. ProShare Advisors LLC now owns 932,624 shares of the company’s stock worth $163,676,000 after acquiring an additional 277,765 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Astrazeneca by 0.7% during the 4th quarter. HighTower Advisors LLC now owns 965,247 shares of the company’s stock worth $169,401,000 after acquiring an additional 7,012 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. grew its stake in shares of Astrazeneca by 5.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 56,328 shares of the company’s stock worth $9,886,000 after acquiring an additional 2,819 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

Positive Sentiment: AstraZeneca and Daiichi Sankyo won FDA approval for Enhertu in two additional early-stage HER2-positive breast cancer settings, expanding the drug’s addressable market and strengthening the company’s oncology pipeline. AZN, Daiichi’s Enhertu Gets FDA Nod for Two New Breast Cancer Settings
Positive Sentiment: The FDA also approved Baxfendy (baxdrostat), AstraZeneca’s first-in-class hypertension drug, which could become a meaningful new growth driver in a large cardiovascular market and may support expectations for multibillion-dollar peak sales. AstraZeneca’s blood pressure drug wins U.S. approval
Neutral Sentiment: Some commentary on the FDA wins raised questions about valuation and the pace of long-term growth, suggesting investors may balance the near-term enthusiasm against execution and pricing concerns. AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation
Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for AstraZeneca to $10.17 from $10.25, though that remains close to the consensus of $10.26 and does not materially change the earnings outlook.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Citigroup initiated coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $205.33.

Read Our Latest Research Report on AZN

Astrazeneca Price Performance

NYSE:AZN opened at $184.69 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock’s 50-day simple moving average is $191.97 and its 200 day simple moving average is $182.43. The company has a market cap of $286.44 billion, a P/E ratio of 27.73, a P/E/G ratio of 1.51 and a beta of 0.26. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71.

Astrazeneca (NYSE:AZN – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, sell-side analysts forecast that Astrazeneca Plc will post 10.25 EPS for the current fiscal year.

About Astrazeneca

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.